Please login to the form below

Not currently logged in

Sanofi announces positive phase 3 data for Dupixent

Research shows significant improvements in signs and symptoms of prurigo nodularis


Sanofi has announced positive phase 3 data showing that nearly three times as many Dupixent patients experienced lower rates of itching and skin lesions at 24 weeks compared to the placebo.

Detailed positive results from the phase 3 prime trial evaluating Dupixent – also known as dupilumab – in adults with uncontrolled prurigo nodularis were presented at a session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress.

In total, 22 scientific abstracts are being presented at the EADV 2022 Congress discussing Dupixent in atopic dermatitis in patients as young as six months – and its investigational use in chronic spontaneous urticaria and bullous pemphigoid – in addition to prurigo nodularis.

The late-breaking data presented at the EADV 2022 Congress are from the randomised, placebo-controlled phase 3 Prime trial, which met its primary and key secondary endpoints. At 24 weeks, among patients treated with Dupixent in the trial, more than three times as many (60%) experienced a clinically meaningful reduction in itch from baseline, the primary endpoint, compared to placebo patients, while nearly three times as many (48%) achieved clear or almost clear skin.

Gil Yosipovitch, Director of the Miami Itch Center, explained: “These positive results from the second of two dupilumab phase 3 trials in prurigo nodularis confirm inhibiting IL-4 and IL-13 can significantly reduce the unrelenting itch and extensive severe skin lesions that often impair patient quality of life.”

He added: “In my practice, relieving itch and clearing skin are often the top priorities for my patients across a range of chronic skin diseases. These data demonstrate dupilumab has the potential to address and manage these debilitating symptoms in another chronic skin disease with underlying type 2 inflammation.”

The impact of uncontrolled prurigo nodularis on quality of life is one of the highest among inflammatory skin diseases and is comparable to other debilitating chronic diseases that can negatively affect mental health, activities of daily living and social interactions.

Article by
John Pinching

9th September 2022

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....